Zacks Investment Research Research Analysts Lift Earnings Estimates for Brainstorm Cell Therapeutics Inc (BCLI)

Share on StockTwits

Brainstorm Cell Therapeutics Inc (NASDAQ:BCLI) – Research analysts at Zacks Investment Research increased their FY2018 earnings per share (EPS) estimates for shares of Brainstorm Cell Therapeutics in a research report issued to clients and investors on Tuesday, October 30th. Zacks Investment Research analyst D. Bautz now forecasts that the biotechnology company will post earnings of ($0.61) per share for the year, up from their prior estimate of ($0.62).

Brainstorm Cell Therapeutics (NASDAQ:BCLI) last posted its quarterly earnings results on Monday, October 29th. The biotechnology company reported ($0.15) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.10) by ($0.05).

BCLI has been the topic of a number of other research reports. HC Wainwright set a $11.00 price target on shares of Brainstorm Cell Therapeutics and gave the stock a “buy” rating in a research note on Monday, August 27th. Maxim Group set a $9.00 price objective on Brainstorm Cell Therapeutics and gave the company a “buy” rating in a report on Sunday, July 8th.

BCLI opened at $3.26 on Thursday. Brainstorm Cell Therapeutics has a fifty-two week low of $2.88 and a fifty-two week high of $5.35. The firm has a market cap of $64.61 million, a price-to-earnings ratio of -12.52 and a beta of 2.01.

A hedge fund recently raised its stake in Brainstorm Cell Therapeutics stock. Renaissance Technologies LLC lifted its holdings in Brainstorm Cell Therapeutics Inc (NASDAQ:BCLI) by 29.5% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 115,400 shares of the biotechnology company’s stock after buying an additional 26,299 shares during the quarter. Renaissance Technologies LLC owned about 0.56% of Brainstorm Cell Therapeutics worth $450,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 11.78% of the company’s stock.

About Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of central nervous system (CNS) adult stem cell therapies designed to address the unmet medical needs of patients with debilitating neurodegenerative diseases. The company holds rights to develop and commercialize its NurOwn technology that utilizes a patient's own cells, which are engineered outside the body, to produce and secrete factors known to promote neuronal survival.

Further Reading: Fundamental Analysis – How It Helps Investors

Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply